WeQual: Eight Exceptional Women Executives Honoured in EMEA Diversity Awards
15.12.2020 18:17:00 EET | Business Wire | Press release
Eight businesswomen holding prominent executive roles in leading companies in Europe, the Middle East and Africa have been named as winners in the annual WeQual Awards (www.wequal.com/awards).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005796/en/
WeQual EMEA 2020 - Winners (Photo: Business Wire)
WeQual identifies and recognises world-class women executives, one level below the group C-suite, and is designed to promote diversity and gender equality within the group executive committees of EMEA’s largest companies.
The eight winners were selected from a shortlist of 24 finalists. The successful award holders are employed in Aryzta, Bayer’s Consumer Health Division, Bureau Veritas, Fresenius Medical Care, Ooredoo Qatar, Sodexo, Standard Chartered Bank and Unilever.
Katie Litchfield, Founder and CEO of WeQual, says: “WeQual identifies already successful senior women who are qualified to be appointed to the group C-suite. Our mission is to tackle the slow progress in appointing diverse women to executive roles and highlight successes where they occur.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the group C-suite, so it is important to champion gender equality at the top.”
The awards come at an important time for women in business. The global Covid-19 pandemic is in danger of pushing back opportunities for women to be appointed to the most senior positions. “The fact that we are able to celebrate the achievements of these women in major companies at this time sets a shining example to others,” says Katie Litchfield.
The winners are:
− Bola Adesola: Senior Vice-Chairman, Africa, Standard Chartered Bank, Nigeria. Head of Region Category.
− Dr Cora Koppe-Stahrenberg: Executive Vice President, Global Head of Human Resources, Fresenius Medical Care, Germany. People Excellence Category.
− Munera AL-Dosari: Chief Strategy Officer, Ooredoo Qatar. Strategy Development Category.
− Patricia Amaro: Digital Hub and E-commerce Director, Unilever, Spain. Digital Impact Category.
− Patricia Corsi: Global Chief Marketing and Digital Officer, Bayer’s Consumer Health Division, Switzerland. Brand Innovation Category.
− Nathalie Pousin: Chief Financial Officer, France, Africa, GSIT, Bureau Veritas, France. Finance Category.
− Petra Melander: EMEA Account Director, Sodexo, Finland. Commercial Performance Category.
− Rebeca Navarro: Chief Transformation Officer for Europe and Head of Procurement, Aryzta, Switzerland. Transformational Leadership Category.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive and Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
To choose the winners, eight executive interviewers held 30-minute interviews with the three finalists in each category before each choosing a category winner. The judges were:
− Sir Ian Cheshire, Chairman, Barclays UK
− Viswas Raghavan, CEO EMEA, J.P. Morgan
− Warren East, CEO, Rolls-Royce
− Dame Inga Beale, Chairperson, Mediclinic
− Chris O'Shea, CEO, Centrica
− Ron Kalifa OBE, Chairman, Network International
− Tamara Box, Managing Partner EME, Reed Smith LLP
− Tulsi Naidu, CEO, Zurich Insurance Company UK
All the 24 award finalists have been given access to a range of WeQual support services and networks designed to help them make the step up to the group executive level. A quarter of WeQual award winners in the UK and USA have since been promoted to the global executive committees of FTSE and Fortune 500 companies. There are now 96 senior women involved with WeQual globally.
(Ends)
Notes to editors
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Group Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they deserve to be appointed to the Group Executive Committee.
- LinkedIn: https://www.linkedin.com/company/wequal-awards
- Twitter: https://twitter.com/WeQualGlobal
- YouTube: https://www.youtube.com/channel/UCBpixTLeUsQVjwrivAP9-KA
- Facebook: https://www.facebook.com/WeQualAwards
- Instagram: https://www.instagram.com/wequalglobal
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005796/en/
Contact information
Katie Litchfield
katie@wequal.com
Mobile: + 44 7796 147466
UK office: +44 20 3290 3389
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
